{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:41:42Z","timestamp":1785400902600,"version":"3.56.0"},"reference-count":102,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001793","name":"Queensland University of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001793","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/03pnv4752","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Iron is an essential element for almost all living beings. Ferroportin is the only known cellular iron exporter and is responsible for maintaining iron homeostasis. The hepcidin-ferroportin axis is central to iron regulation. Dysregulation of ferroportin is thus associated with iron disorders. Understanding how ferroportin is regulated will provide greater insight into iron metabolism and potential therapies for iron-related disease. This review synthesizes current knowledge on ferroportin biology with a particular focus on its regulatory modulators and their therapeutic potential and provides an updated perspective on the molecular pathogenesis and clinical spectrum of ferroportin disease. Elucidating these mechanisms will be essential for the development of targeted interventions to correct iron dysregulation in diverse human diseases.<\/jats:p>","DOI":"10.3390\/biom16071066","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:17:52Z","timestamp":1784647072000},"page":"1066","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ferroportin at the Crossroads of Iron Biology: Disease, Regulation and Modulation"],"prefix":"10.3390","volume":"16","author":[{"given":"Pramudi Hasanga","family":"Rathnayake","sequence":"first","affiliation":[{"name":"Hepatogenomics Research Group, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"},{"name":"Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina E.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"},{"name":"Metallogenomics Laboratory, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1247-4663","authenticated-orcid":false,"given":"Ryan","family":"Atkins","sequence":"additional","affiliation":[{"name":"Hepatogenomics Research Group, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"},{"name":"Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6019-9424","authenticated-orcid":false,"given":"Daniel F.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"},{"name":"Metallogenomics Laboratory, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4583-7790","authenticated-orcid":false,"given":"V. Nathan","family":"Subramaniam","sequence":"additional","affiliation":[{"name":"Hepatogenomics Research Group, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"},{"name":"Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, Brisbane, QLD 4059, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.tips.2021.05.001","article-title":"Iron metabolism: Pathophysiology and pharmacology","volume":"42","author":"Roemhild","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41580-023-00648-1","article-title":"Mechanisms controlling cellular and systemic iron homeostasis","volume":"25","author":"Galy","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_3","first-page":"51","article-title":"The Regulation of Iron Absorption and Homeostasis","volume":"37","author":"Wallace","year":"2016","journal-title":"Clin. Biochem. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.26001","article-title":"Cell-type-specific insights into iron regulatory processes","volume":"96","author":"Silvestri","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Vogt, A.S., Arsiwala, T., Mohsen, M., Vogel, M., Manolova, V., and Bachmann, M.F. (2021). On Iron Metabolism and Its Regulation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094591"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jare.2025.01.002","article-title":"Mechanism and regulation of iron absorption throughout the life cycle","volume":"77","author":"Qiu","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41586-020-2668-z","article-title":"Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms","volume":"586","author":"Azumaya","year":"2020","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"ref_9","unstructured":"World Health Organisation (2026, February 03). Anaemia. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/anaemia."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e44380","DOI":"10.1097\/MD.0000000000044380","article-title":"Global, regional, and national burden of anemia, 1990 to 2021: An observational study analysis for the global burden of disease","volume":"104","author":"Luo","year":"2025","journal-title":"Medicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/s41591-025-03624-8","article-title":"Global, regional and national burden of dietary iron deficiency from 1990 to 2021: A Global Burden of Disease study","volume":"31","author":"Lee","year":"2025","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kawabata, T. (2022). Iron-Induced Oxidative Stress in Human Diseases. Cells, 11.","DOI":"10.3390\/cells11142152"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tan, X., Tian, Y., Zhang, T., Yao, Q., Zhu, T., Wang, W., Wang, Q., and Fu, H. (2026). Oral iron preparations: Gastrointestinal adverse events and medication adherence in female patients with iron deficiency anemia. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1727566"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/ejh.13892","article-title":"The role of oral iron in the treatment of adults with iron deficiency","volume":"110","author":"Lo","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/microbiolres12020033","article-title":"Oral Iron Supplementation\u2014Gastrointestinal Side Effects and the Impact on the Gut Microbiota","volume":"12","author":"Bloor","year":"2021","journal-title":"Microbiol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10620-022-07599-1","article-title":"Ironing It All Out: A Comprehensive Review of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients","volume":"68","author":"Maas","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.20452\/pamw.2888","article-title":"Treatment of iron deficiency anemia: Practical considerations","volume":"125","author":"Taylor","year":"2015","journal-title":"Pol. Arch. Med. Wewn."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/PROM.S532952","article-title":"Perspectives on Intravenous Iron Therapy Logistics and Adherence: Results from a Patient Survey","volume":"16","author":"Lee","year":"2025","journal-title":"Patient Relat. Outcome Meas."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/JBM.S108479","article-title":"Clinical applications of therapeutic phlebotomy","volume":"7","author":"Kim","year":"2016","journal-title":"J. Blood Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/trf.17862","article-title":"Adverse effects of therapeutic phlebotomies: Prospective study of 587 procedures","volume":"64","author":"Calzada","year":"2024","journal-title":"Transfusion"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.hoc.2022.12.013","article-title":"Clinical Challenges with Iron Chelation in Beta Thalassemia","volume":"37","author":"Kwiatkowski","year":"2023","journal-title":"Hematol. Oncol. Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"212502","DOI":"10.7573\/dic.212502","article-title":"Advances in iron chelation therapy: Transitioning to a new oral formulation","volume":"6","author":"Shah","year":"2017","journal-title":"Drugs Context"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J. (2023). Drug Selection and Posology, Optimal Therapies and Risk\/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316749"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1097\/MS9.0000000000001717","article-title":"Iron chelators: As therapeutic agents in diseases","volume":"86","author":"Salimi","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19906","DOI":"10.1074\/jbc.M000713200","article-title":"A novel mammalian iron-regulated protein involved in intracellular iron metabolism","volume":"275","author":"Abboud","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/35001596","article-title":"Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter","volume":"403","author":"Donovan","year":"2000","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1097-2765(00)80425-6","article-title":"A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation","volume":"5","author":"McKie","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e82947","DOI":"10.7554\/eLife.82947","article-title":"Mechanism of Ca2+ transport by ferroportin","volume":"12","author":"Shen","year":"2023","journal-title":"eLife"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2025.10.016","article-title":"Characterization of ferroportin disease and SLC40A1-related hemochromatosis\u2014Results from the EASL non-HFE registry","volume":"84","author":"Troppmair","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e70821","DOI":"10.1096\/fj.202500790RR","article-title":"Identification of New Key Players for Ferrous Iron Export in the Asymmetric Inner Gate of Human Ferroportin 1","volume":"39","author":"Elbahnsi","year":"2025","journal-title":"FASEB J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"C75","DOI":"10.1152\/ajpcell.00621.2008","article-title":"Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype","volume":"298","author":"Wallace","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1038\/ncomms9545","article-title":"Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin","volume":"6","author":"Taniguchi","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2017-05-786590","article-title":"Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin","volume":"131","author":"Aschemeyer","year":"2018","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e83053","DOI":"10.7554\/eLife.83053","article-title":"Structures of ferroportin in complex with its specific inhibitor vamifeport","volume":"12","author":"Lehmann","year":"2023","journal-title":"eLife"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"18016","DOI":"10.1038\/nrdp.2018.16","article-title":"Haemochromatosis","volume":"4","author":"Brissot","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.2021011338","article-title":"Hemochromatosis classification: Update and recommendations by the BIOIRON Society","volume":"139","author":"Girelli","year":"2022","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2018-02-830562","article-title":"Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease","volume":"132","author":"Sandhu","year":"2018","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1182\/blood-2004-11-4502","article-title":"In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations","volume":"105","author":"Schimanski","year":"2005","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3324\/haematol.2017.170720","article-title":"Ferroportin disease: Pathogenesis, diagnosis and treatment","volume":"102","author":"Pietrangelo","year":"2017","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jhep.2021.10.022","article-title":"A simple clinical score to promote and enhance ferroportin disease screening","volume":"76","author":"Landemaine","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jhep.2010.05.016","article-title":"Ferroportin disease: A systematic meta-analysis of clinical and molecular findings","volume":"53","author":"Mayr","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100335","DOI":"10.1016\/j.xhgg.2024.100335","article-title":"The dual loss and gain of function of the FPN1 iron exporter results in the ferroportin disease phenotype","volume":"5","author":"Uguen","year":"2024","journal-title":"Hum. Genet. Genom. Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/90038","article-title":"A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis","volume":"28","author":"Njajou","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1445-5994.1990.tb01024.x","article-title":"Familial iron overload with possible autosomal dominant inheritance","volume":"20","author":"Eason","year":"1990","journal-title":"Aust. N. Z. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/gut.52.8.1215","article-title":"A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient","volume":"52","author":"Arden","year":"2003","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199909023411003","article-title":"Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene","volume":"341","author":"Pietrangelo","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI200113468","article-title":"Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene","volume":"108","author":"Montosi","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"14625","DOI":"10.1096\/fj.201901857R","article-title":"Molecular model of the ferroportin intracellular gate and implications for the human iron transport cycle and hemochromatosis type 4A","volume":"33","author":"Guellec","year":"2019","journal-title":"FASEB. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/gim.2015.140","article-title":"The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data","volume":"18","author":"Wallace","year":"2016","journal-title":"Genet. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3945\/an.116.013961","article-title":"Regulation of the Iron Homeostatic Hormone Hepcidin","volume":"8","author":"Sangkhae","year":"2017","journal-title":"Adv. Nutr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1182\/blood-2011-01-330241","article-title":"Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cmet.2012.03.018","article-title":"Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination","volume":"15","author":"Qiao","year":"2012","journal-title":"Cell Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cmet.2012.03.017","article-title":"Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT","volume":"15","author":"Ross","year":"2012","journal-title":"Cell Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjh.17252","article-title":"Physiological and pathophysiological mechanisms of hepcidin regulation: Clinical implications for iron disorders","volume":"193","author":"Xu","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"809","DOI":"10.15252\/embr.201338064","article-title":"sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin","volume":"15","author":"McCarthy","year":"2014","journal-title":"EMBO Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1006\/bcmd.2002.0572","article-title":"Role of the ferroportin iron-responsive element in iron and nitric oxide dependent gene regulation","volume":"29","author":"Liu","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1002\/jcp.27522","article-title":"Hepcidin and iron regulatory proteins coordinately regulate ferroportin 1 expression in the brain of mice","volume":"234","author":"Wang","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.seminhematol.2021.06.001","article-title":"Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization","volume":"58","author":"Maio","year":"2021","journal-title":"Semin. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/MCB.01111-06","article-title":"Iron-dependent degradation of apo-IRP1 by the ubiquitin-proteasome pathway","volume":"27","author":"Wang","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"103131","DOI":"10.1016\/j.redox.2024.103131","article-title":"MAPK15 controls cellular responses to oxidative stress by regulating NRF2 activity and expression of its downstream target genes","volume":"72","author":"Franci","year":"2024","journal-title":"Redox Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1089\/ars.2017.7176","article-title":"The Roles of NRF2 in Modulating Cellular Iron Homeostasis","volume":"29","author":"Kerins","year":"2018","journal-title":"Antioxid. Redox Signal"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41420-022-01117-y","article-title":"Interplay of Nrf2 and BACH1 in inducing ferroportin expression and enhancing resistance of human macrophages towards ferroptosis","volume":"8","author":"Namgaladze","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.abb.2011.02.001","article-title":"Nrf2 regulates ferroportin 1-mediated iron efflux and counteracts lipopolysaccharide-induced ferroportin 1 mRNA suppression in macrophages","volume":"508","author":"Harada","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/s41401-024-01336-2","article-title":"The regulation and function of Nrf2 signaling in ferroptosis-activated cancer therapy","volume":"45","author":"Jiang","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3324\/haematol.2009.020123","article-title":"Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE\/ARE sequence motif at position -7007 of the FPN1 promoter","volume":"95","author":"Marro","year":"2010","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kasai, S., Mimura, J., Ozaki, T., and Itoh, K. (2018). Emerging Regulatory Role of Nrf2 in Iron, Heme, and Hemoglobin Metabolism in Physiology and Disease. Front. Vet. Sci., 5.","DOI":"10.3389\/fvets.2018.00242"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e20191314","DOI":"10.1084\/jem.20191314","article-title":"PPAR\u03b3 is essential for the development of bone marrow erythroblastic island macrophages and splenic red pulp macrophages","volume":"218","author":"Okreglicka","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41421-022-00388-0","article-title":"PPAR\u03b3 phase separates with RXR\u03b1 at PPREs to regulate target gene expression","volume":"8","author":"Li","year":"2022","journal-title":"Cell Discov."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/MCB.01651-09","article-title":"Cell-specific determinants of peroxisome proliferator-activated receptor \u03b3 function in adipocytes and macrophages","volume":"30","author":"Lefterova","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/eji.200939889","article-title":"Differential regulation of iron homeostasis during human macrophage polarized activation","volume":"40","author":"Recalcati","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2011-09-380337","article-title":"Deletion of HIF-2\u03b1 in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice","volume":"119","author":"Mastrogiannaki","year":"2012","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2\u03b1 mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","article-title":"Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency","volume":"9","author":"Shah","year":"2009","journal-title":"Cell Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bcmd.2012.08.002","article-title":"Cell-specific regulation of Ferroportin transcription following experimentally-induced acute anemia in mice","volume":"50","author":"Chiabrando","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/blood-2010-04-278614","article-title":"Induction of FPN1 transcription by MTF-1 reveals a role for ferroportin in transition metal efflux","volume":"116","author":"Troadec","year":"2010","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nri3863","article-title":"Iron homeostasis in host defence and inflammation","volume":"15","author":"Ganz","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Charlebois, E., and Pantopoulos, K. (2021). Iron overload inhibits BMP\/SMAD and IL-6\/STAT3 signaling to hepcidin in cultured hepatocytes. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253475"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Xia, Y., Li, Y., Wu, X., Zhang, Q., Chen, S., Ma, X., and Yu, M. (2021). Ironing Out the Details: How Iron Orchestrates Macrophage Polarization. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.669566"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.2023023417","article-title":"Inflammation-driven NF-\u03baB signaling represses ferroportin transcription in macrophages via HDAC1 and HDAC3","volume":"145","author":"Marques","year":"2025","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Sangokoya, C., Doss, J.F., and Chi, J.T. (2013). Iron-responsive miR-485-3p regulates cellular iron homeostasis by targeting ferroportin. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003408"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2843990","DOI":"10.1155\/2022\/2843990","article-title":"MicroRNA-147a Targets SLC40A1 to Induce Ferroptosis in Human Glioblastoma","volume":"2022","author":"Xu","year":"2022","journal-title":"Anal. Cell Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4213401","DOI":"10.1155\/2022\/4213401","article-title":"MicroRNA-4735-3p Facilitates Ferroptosis in Clear Cell Renal Cell Carcinoma by Targeting SLC40A1","volume":"2022","author":"Zhu","year":"2022","journal-title":"Anal. Cell Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Jiang, S., Fang, X., Liu, M., Ni, Y., Ma, W., and Zhao, R. (2019). MiR-20b Down-Regulates Intestinal Ferroportin Expression In Vitro and In Vivo. Cells, 8.","DOI":"10.3390\/cells8101135"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00109-015-1362-3","article-title":"MiR-20a regulates expression of the iron exporter ferroportin in lung cancer","volume":"94","author":"Babu","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-nutr-071813-105646","article-title":"Bone morphogenetic proteins as regulators of iron metabolism","volume":"34","author":"Parrow","year":"2014","journal-title":"Annu. Rev. Nutr."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"115495","DOI":"10.1016\/j.bone.2020.115495","article-title":"Bone morphogenic proteins in iron homeostasis","volume":"138","author":"Xiao","year":"2020","journal-title":"Bone"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.vh.2019.01.004","article-title":"Hepcidin and the BMP-SMAD pathway: An unexpected liaison","volume":"110","author":"Silvestri","year":"2019","journal-title":"Vitam. Horm."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Hawula, Z.J., Wallace, D.F., Subramaniam, V.N., and Rishi, G. (2019). Therapeutic Advances in Regulating the Hepcidin\/Ferroportin Axis. Pharmaceuticals, 12.","DOI":"10.3390\/ph12040170"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14728222.2024.2443081","article-title":"Hepcidin as a therapeutic target in iron overload","volume":"28","author":"Sandnes","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Katsarou, A., and Pantopoulos, K. (2018). Hepcidin Therapeutics. Pharmaceuticals, 11.","DOI":"10.3390\/ph11040127"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood-2014-10-606491","article-title":"Hepcidin is suppressed by erythropoiesis in hemoglobin E \u03b2-thalassemia and \u03b2-thalassemia trait","volume":"125","author":"Jones","year":"2015","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/ejh.14243","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study","volume":"113","author":"Modi","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa2308809","article-title":"Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera","volume":"390","author":"Kremyanskaya","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.clinthera.2025.09.002","article-title":"Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants","volume":"47","author":"Modi","year":"2025","journal-title":"Clin. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1172\/JCI57693","article-title":"Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload","volume":"121","author":"Preza","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Renders, L., Budde, K., Rosenberger, C., van Swelm, R., Swinkels, D., Dellanna, F., Feuerer, W., Wen, M., Erley, C., and Bader, B. (2019). First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212023"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia","volume":"10","author":"Abonour","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s12325-022-02421-w","article-title":"TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis","volume":"40","author":"Ganz","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e191813","DOI":"10.1172\/jci.insight.191813","article-title":"A TMPRSS6-inhibiting mAb improves disease in a \u03b2-thalassemia mouse model and reduces iron in healthy humans","volume":"10","author":"Lob","year":"2025","journal-title":"JCI Insight"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/ajh.27015","article-title":"SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers","volume":"98","author":"Porter","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Pilo, F., and Angelucci, E. (2024). Vamifeport: Monography of the First Oral Ferroportin Inhibitor. J. Clin. Med., 13.","DOI":"10.3390\/jcm13185524"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1182\/blood.V122.21.3433.3433","article-title":"LY2928057, An Antibody Targeting Ferroportin, Is a Potent Inhibitor Of Hepcidin Activity and Increases Iron Mobilization In Normal Cynomolgus Monkeys","volume":"122","author":"Witcher","year":"2013","journal-title":"Blood"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/7\/1066\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:10:46Z","timestamp":1784779846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/7\/1066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":102,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["biom16071066"],"URL":"https:\/\/doi.org\/10.3390\/biom16071066","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}